| Literature DB >> 30001913 |
Lijuan Zhang1, Xuan Cui2, Ruben Jauregui3, Karen Sophia Park4, Sally Justus5, Yi-Ting Tsai4, Jimmy K Duong6, Chun-Wei Hsu4, Wen-Hsuan Wu4, Christine L Xu4, Chyuan-Sheng Lin7, Stephen H Tsang8.
Abstract
Microglia cells (MGCs) play a key role in scavenging pathogens and phagocytosing cellular debris in the central nervous system and retina. Their activation, however, contributes to the progression of multiple degenerative diseases. Given the potential damage created by MGCs, it is important to better understand their mechanism of activation. Here, we explored the role of MGCs in the context of retinitis pigmentosa (RP) by using four independent preclinical mouse models. For therapeutic modeling, tamoxifen-inducible CreER was introduced to explore changes in MGCs when RP progression halted. The phenotypes of the MGCs were observed using live optical coherence tomography, live autofluorescence, and immunohistochemistry. We found that, regardless of genetic background, MGCs were activated in neurodegenerative conditions and migrated beyond the layers where they are typically found to the inner and outer segments, where degeneration was ongoing. Genetic rescue not only halted degeneration but also deactivated MGCs, regardless of whether the intervention occurred at the early, middle, or late stage of the disease. These findings suggest that halting long-term disease progression may be more successful by downregulating MGC activity while co-administering the therapeutic intervention.Entities:
Keywords: Cre recombinase; Pde6 mutation; genetic diseases; microglia cells; retinitis pigmentosa
Mesh:
Substances:
Year: 2018 PMID: 30001913 PMCID: PMC6094486 DOI: 10.1016/j.ymthe.2018.06.014
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454